Antimicrobial resistance (AMR) is emerging as one of the most serious threats to global health, with the World Health Organization (WHO) warning that drug-resistant infections could claim approximately 39 million lives between now and 2050 if urgent action is not taken.
Despite growing international efforts to tackle the problem, WHO officials say progress remains too slow, particularly in preventing infections, improving diagnostic facilities and ensuring antibiotics are used responsibly.
Antimicrobial resistance occurs when bacteria, viruses, fungi and parasites develop the ability to survive medicines designed to eliminate them. As these microorganisms become resistant to treatment, infections become increasingly difficult to manage, raising the risk of severe illness, complications and death.
The widespread and sometimes inappropriate use of antibiotics in healthcare, animal farming and food production has accelerated the problem. What was once considered a manageable medical challenge is now threatening the effectiveness of treatments that millions of people depend on every day.
Jean-Pierre Nyemazi, interim head of antimicrobial resistance at WHO, described the situation as a growing danger to modern medicine.
He warned that, unlike the COVID-19 pandemic, which attracted immediate global attention, antimicrobial resistance has been silently taking lives for years without receiving the level of public awareness and urgency it deserves.
According to WHO estimates, antimicrobial resistance was directly responsible for more than one million deaths in 2021 and associated with approximately 4.7 million additional deaths. These figures highlight the enormous human cost of infections that no longer respond effectively to available medicines.
Countries are making progress, but implementation remains a challenge
A WHO assessment covering 183 countries revealed improvements in national efforts to address antimicrobial resistance. Nearly nine out of 10 countries now have a national action plan to tackle the issue, compared with approximately four out of 10 in 2017.
However, having a plan does not necessarily mean that meaningful action is taking place.
Only 42 countries, representing fewer than one in five, reported having national plans that were fully financed, implemented and monitored.
Pravasha Prakash, an AMR technical officer at WHO, acknowledged that countries were making progress but stressed that much more needed to be done to achieve the global targets set for 2030.
The findings underline an important gap between policy commitments and practical implementation. Without adequate funding, trained professionals, laboratory facilities and consistent monitoring, even well-designed national strategies may struggle to deliver meaningful results.
Limited diagnostic facilities are putting patients at greater risk
One of the biggest challenges in controlling antimicrobial resistance is the lack of access to reliable diagnostic testing.
WHO reported that only 36 per cent of countries had a national reference laboratory capable of testing resistance across all the bacteria and fungi monitored by the organisation. This remains considerably below the 80 per cent target established for 2030.
Without proper testing, healthcare professionals may have to prescribe antibiotics without knowing exactly which microorganism is causing an infection or which medicine is most likely to work.
Sylvia Bertagnolo, WHO’s head of antimicrobial resistance surveillance, highlighted the importance of laboratory testing in helping doctors make informed treatment decisions.
The latest global surveillance findings also reveal the seriousness of the situation. In 2023, approximately one in every six laboratory-confirmed bacterial infections reported to WHO was resistant to the antibiotics used to treat it.
This means that medicines routinely relied upon by healthcare professionals are becoming less effective against an increasing number of infections.
To help countries strengthen their healthcare systems, WHO has introduced two new tools designed to improve diagnostic capabilities.
The first outlines the essential diagnostic tests that should be available throughout healthcare systems, from primary healthcare centres to referral hospitals.
The second provides a collection of 73 laboratory procedures covering different stages of testing, including sample collection, pathogen identification and antibiotic susceptibility testing.
These resources are intended to help healthcare professionals identify infections more accurately and select appropriate treatments before resistance becomes an even greater challenge.
Why the world cannot afford to ignore antimicrobial resistance
WHO estimates that antimicrobial resistance could contribute to approximately 39 million deaths between now and 2050. The warning is particularly concerning because the development of new antibiotics and other treatments is struggling to keep pace with the growing ability of microorganisms to resist existing medicines.
The consequences extend beyond hospitals and healthcare facilities. If commonly used antibiotics become ineffective, routine medical procedures, cancer treatments, organ transplants and surgeries could become significantly more dangerous because of the increased risk of infections that are difficult to treat.
WHO has emphasised that addressing antimicrobial resistance requires a comprehensive approach rather than relying solely on the development of new medicines.
Key priorities include preventing infections through better hygiene, expanding vaccination programmes, improving access to clean water and sanitation, strengthening diagnostic facilities and ensuring that antimicrobial medicines are prescribed and used appropriately.
Responsible antibiotic use is especially important. Taking antibiotics without medical advice, using them for illnesses they cannot treat, failing to follow prescribed instructions or sharing leftover medicines can contribute to inappropriate use and increase the risk of resistance.
The same responsibility extends to agriculture and food production, where unnecessary antimicrobial use must also be addressed.
The future of modern medicine depends on action today
Antimicrobial resistance is not simply a scientific concern or a problem for hospitals to solve. It is a global public health challenge that requires cooperation between governments, healthcare professionals, researchers, farmers, businesses and communities.
The warning from WHO should encourage countries to move beyond announcements and commitments towards practical action. More investment in laboratories, stronger healthcare systems, better public education and responsible medicine use are essential to protecting the effectiveness of treatments.
For ordinary people, the message is equally important: antibiotics are valuable medicines, not a solution for every illness. Using them responsibly today helps protect their effectiveness for tomorrow.
The greatest danger is that society may only recognise the seriousness of antimicrobial resistance when treatments that once saved lives stop working. By then, the consequences could be far more difficult to reverse.
Protecting the power of medicine is a shared responsibility. The decisions made today could determine whether future generations have access to effective treatments when they need them most.

